XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
$ / shares in Units, shares in Thousands
 1 Months Ended 12 Months Ended
May 31, 2017
USD ($)
May 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2021
USD ($)
segment
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2007
$ / shares
Oct. 01, 2020
USD ($)
$ / shares
Apr. 01, 2020
USD ($)
Jan. 01, 2020
USD ($)
Aug. 15, 2019
USD ($)
May 31, 2018
USD ($)
May 22, 2018
USD ($)
Aug. 31, 2014
USD ($)
Jan. 31, 2010
right
Basis of Presentation [Line Items]                              
Number of business segments | segment       1                      
Maturity period of cash and cash equivalents, maximum       3 months                      
Write-downs related to obsolete inventory       $ 0 $ 0 $ 0                  
Inventory       27,326,000 26,487,000                    
Total revenues       277,133,000 186,419,000 120,282,000                  
Additional reserve for credit losses due to COVID-19       $ (500,000) (500,000)                    
Revenue recognized         $ 30,100,000 $ 900,000                  
Dividend declared (USD per share) | $ / shares             $ 2.50                
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares       4,793 8,458 8,926                  
Equity Awards                              
Basis of Presentation [Line Items]                              
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares         600                    
Contract revenue                              
Basis of Presentation [Line Items]                              
Total revenues       $ 63,956,000 $ 42,664,000 $ 41,817,000                  
Captisol                              
Basis of Presentation [Line Items]                              
Inventory       24,600,000 26,100,000                    
Total revenues       $ 164,250,000 109,959,000 $ 31,489,000                  
Stock Options | 2002 Stock Incentive Plan                              
Basis of Presentation [Line Items]                              
Award expiration period       10 years                      
Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan                              
Basis of Presentation [Line Items]                              
Award vesting period       6 months                      
Award vesting right (as a percent)       12.50%                      
Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan                              
Basis of Presentation [Line Items]                              
Award vesting period       42 months                      
Award vesting right (as a percent)       2.08%                      
RSUs and PSUs                              
Basis of Presentation [Line Items]                              
Award vesting period       3 years                      
PSUs                              
Basis of Presentation [Line Items]                              
Award vesting period       3 years                      
Minimum                              
Basis of Presentation [Line Items]                              
Property and equipment, useful life       3 years                      
Minimum | PSUs                              
Basis of Presentation [Line Items]                              
Award vesting right (as a percent)       0.00%                      
Maximum                              
Basis of Presentation [Line Items]                              
Property and equipment, useful life       10 years                      
Maximum | PSUs                              
Basis of Presentation [Line Items]                              
Award vesting right (as a percent)       200.00%                      
Pfenex                              
Basis of Presentation [Line Items]                              
Contingent consideration liability per share (USD per share) | $ / shares               $ 2.00              
Contingent consideration liability               $ 77,800,000              
Icagen                              
Basis of Presentation [Line Items]                              
Contingent consideration liability                 $ 25,000,000            
Metabasis Therapeutics                              
Basis of Presentation [Line Items]                              
Number of contingent value rights | right                             4
Royalty Agreements                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent) 20.00%                            
Licensing Agreements                              
Basis of Presentation [Line Items]                              
Finite-lived intangible assets, net       $ 10,110,000 10,979,000                    
Credit loss adjustments on finite-lived intangible assets       $ 6,500,000 6,000,000                    
Licensing Agreements | Accounting Standards Update 2016-13                              
Basis of Presentation [Line Items]                              
Credit loss adjustments on finite-lived intangible assets                   $ 5,500,000          
Novan | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Additional royalties receivable under sales-based milestones   $ 20,000,000                          
Novan | Royalty Agreements | Minimum                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent)   7.00%                          
Novan | Royalty Agreements | Maximum                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent)   10.00%                          
Novan | Licensing Agreements                              
Basis of Presentation [Line Items]                              
Upfront payment for license   $ 12,000,000                          
Palvella | Contract revenue                              
Basis of Presentation [Line Items]                              
Total revenues         3,000,000                    
Palvella | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Additional royalties receivable under sales-based milestones     $ 8,000,000                        
Palvella | Royalty Agreements | Minimum                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent)     5.00%                        
Palvella | Royalty Agreements | Maximum                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent)     9.80%                        
Palvella | Licensing Agreements                              
Basis of Presentation [Line Items]                              
Upfront payment for license     $ 10,000,000                        
Finite-lived intangible assets, net         0                    
Aziyo | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent) 5.00%                            
Proceeds from royalties received $ 10,000,000                            
Effective interest rate of forecasted cash flows (as a percent)       21.60%                      
Aziyo | Royalty Agreements | Maximum                              
Basis of Presentation [Line Items]                              
Additional royalties receivable under sales-based milestones $ 10,000,000                            
CorMatrix | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Product royalty (as a percent) 5.00%                            
Expiration period of royalty agreement 10 years                            
Selexis | Royalty Agreements                              
Basis of Presentation [Line Items]                              
Effective interest rate of forecasted cash flows (as a percent)       21.00%                      
2023 Convertible Senior Notes | Senior Notes                              
Basis of Presentation [Line Items]                              
Principal amount of 2023 Notes outstanding                       $ 750,000,000      
Interest on debt instrument (as a percent)                       0.75%      
2023 Convertible Senior Notes | Convertible Notes                              
Basis of Presentation [Line Items]                              
Principal amount of 2023 Notes outstanding       $ 343,301,000 $ 495,280,000               $ 750,000,000    
Interest on debt instrument (as a percent)                         0.75%    
2019 Convertible Senior Notes                              
Basis of Presentation [Line Items]                              
Derivative asset                     $ 0        
Derivative liability                     $ 0        
2019 Convertible Senior Notes | Convertible Notes                              
Basis of Presentation [Line Items]                              
Principal amount of 2023 Notes outstanding                           $ 245,000,000  
Interest on debt instrument (as a percent)                           0.75%  
Dividend yield                              
Basis of Presentation [Line Items]                              
Measurement input (as a percent)       0